The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus

Basit Öğe Kaydı
dc.authorwosidTurgut, Burhan/A-2517-2016
dc.contributor.authorGuldiken, S
dc.contributor.authorTurgut, B
dc.contributor.authorDemir, M
dc.contributor.authorArikan, E
dc.contributor.authorKara, M
dc.contributor.authorVural, O
dc.contributor.authorTugrul, A
dc.date.accessioned2024-06-12T11:13:45Z
dc.date.available2024-06-12T11:13:45Z
dc.date.issued2006
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPatients with type 2 diabetes mellitus (DM) are at risk for the development of cardiovascular diseases, which can in part be explained by disturbances in the hemostatic and fibrinolytic systems. The effects of rosiglitazone treatment on the fibrinolytic system and insulin sensitivity in patients with type 2 DM were assessed. Twenty-four patients with type 2 DM and 28 healthy subjects were enrolled in the study. Plasma global fibrinolytic capacity (GFC), tissue plasminogen activator (t-PA), and plasminogen activator inhibitor-1 (PAI-1) levels were measured. Insulin resistance was calculated by hoemostasis model assessment. Patients with type 2 DM then were placed on rosiglitazone (4 mg/day, for 12 weeks) in addition coexistent medication, and baseline tests were repeated. There was no difference between mean t-PA levels of the two groups. PAI-1 levels were higher in diabetic patients than control subjects (p < 0.01). Diabetic patients had lower GFC and t-PA/PAI-1 levels than control subjects (p < 0.05, p < 0.05). PAI-1 levels were positively correlated with waist circumference in diabetic group (r = 0.4, p < 0.05). After rosiglitazone treatment, there was no difference in mean plasma levels of GFQ t-PA, PAI-1 and t-PA/PAI-1 in diabetics. Insulin sensitivity significantly improved after the addition of rosiglitazone treatment in diabetic patients (p < 0.01). The short-term and low-dose treatment with rosiglitazone in type 2 diabetic patients has no effects on the fibrinolytic system, although it improves insulin sensitivity.en_US
dc.identifier.doi10.1177/107602960601200109
dc.identifier.endpage60en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue1en_US
dc.identifier.pmid16444435en_US
dc.identifier.scopus2-s2.0-32344447682en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage55en_US
dc.identifier.urihttps://doi.org/10.1177/107602960601200109
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23672
dc.identifier.volume12en_US
dc.identifier.wosWOS:000235089800009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRosiglitazoneen_US
dc.subjectType 2 Diabetes Mellitusen_US
dc.subjectFibrinolytic Systemen_US
dc.subjectInsulin Resistanceen_US
dc.subjectPlasminogen-Activator Inhibitor-1en_US
dc.subjectInsulin-Resistanceen_US
dc.subjectCardiovascular-Diseaseen_US
dc.subjectHemostatic Systemen_US
dc.subjectVascular-Diseaseen_US
dc.subjectRisk Factoren_US
dc.subjectPlasmaen_US
dc.subjectCoagulationen_US
dc.subjectPrecursorsen_US
dc.subjectIncreasesen_US
dc.titleThe effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu